Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Instituto de Salud Carlos III | OTHER_GOV |
| Spanish Society of Cardiology | OTHER |
Not provided
Not provided
Not provided
Not provided
This study evaluates the efficacy and safety of an individualized preventive strategy against CMV infection in CMV seropositive heart transplant patients based on the specific basal response of the lymphocytes againts CMV (ELISPOT Interferon-γ assay).
In two thirds of the patients a preventive strategy will be carried out based on the result of the ELISPOT IFN-γ assay and in one third of the patients the standard of care strategy will be carried out (universal prophylaxis).
Background: The prevention of Cytomegalovirus (CMV) infection in cardiac transplant patients is currently based exclusively on the performance of the serotypes of the receptor and the donor. Despite prophylactic treatment with valganciclovir or preemptive therapy through serial monitoring of blood viral copies, the rate of infection or CMV disease remains high and has a negative clinical impact. The evaluation of the specific T lymphocytes cellular immune response against 2 CMV antigens prior to kidney transplantaction, using the ELISPOT IFN-γ assay discriminates in a better way which patients will develop CMV infection.
Objetives: To compare the cumulative incidence of CMV infection during the first year post-heart transplant amongst CMV seropositive recipients in 12 national centers, where the prophylactic strategy regarding CMV infection will be guided by the ELISPOT IFN-γ assay or not (control). Main variable: number of patients who have CMV infection in the first year post-trasplant (HT).
Hyphotesis: A preventive strategy against CMV infection in CMV seropositive heart transplant patients, based on the specific basal response of the T lymphocytes against CMV, ELISPOT IFN-γ assay, is effective, safe and not inferior than the control group in terms of infection CMV rates. Design: The investigators propose a phase IV clinical trial (with authorized treatment), randomized (2:1), controlled, open label and multicentric, with two parallel groups (Experimental group: preventive strategy based on the ELISPOT IFN-γ result: If patients are stratified as high risk they will receive prophylaxis with valgancyclovir for 3 months and if they are stratified as low risk they will be treated with preemptive therapy guided by CMV polymerase chain reaction analysis; Control group: Standard of care, universal prophylaxis with valgancyclovir for 3 months).
Follow-up: 1 year. Duration of the trial: 3 years. Sample size: 188 patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental group | Experimental | Preventive strategy based on the ELISPOT IFN-γ result: If patients are stratified as high risk they will receive prophylaxis with valgancyclovir for 3 months and if they are stratified as low risk they will be treated with preemptive therapy guided by CMV polymerase chain reaction analysis; |
|
| Control group | No Intervention | Standard of care, universal prophylaxis with valgancyclovir for 3 months). |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ELISPOT IFN-γ assay | Diagnostic Test | ELISPOT IFN-γ diagnostic test: Evaluation of specific cellular immune response against the IE-1 antigen and the CMV pp65, using the technique ELISPOT IFN-γ and individualize the preventive strategy according to the result. In patients with a ELISPOT of "low risk" will be made advance therapy (preemptive therapy) guided by PCR of CMV In patients with a "high risk" ELISPOT, universal prophylaxis with valganciclovir will be performed oral (900 mg / 24h) or intravenous ganciclovir (5-10 mg / Kd / day) in case the oral route is not available. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients who have CMV infection in the first year post heart transplant. | Any viremia | One year |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with late CMV infection. | Number of patients with late CMV infection who have received prophylaxis with valganciclovir or ganciclovir (group 1 a and control group), once the treatment is finished. | One year |
| Number of patients with acute rejection. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jose González Costello | Contact | +0034 932607686 | jgonzalez@bellvitgehospital.cat | |
| Elena García Romero | Contact | e.garcia.r@bellvitgehospital.cat |
| Name | Affiliation | Role |
|---|---|---|
| José González Costello | Cardiologist | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Universitari de Bellvitge | Recruiting | Barcelona | 08907 | Spain |
Not provided
Phase IV clinical trial (with authorized treatment), randomized (2:1), controlled, open label and multicentric, with two parallel groups (Experimental group: preventive strategy based on the ELISPOT IFN-γ result: If patients are stratified as high risk they will receive prophylaxis with valgancyclovir for 3 months and if they are stratified as low risk they will be treated with preemptive therapy guided by CMV polymerase chain reaction analysis; Control group: Standard of care, universal prophylaxis with valgancyclovir for 3 months).
Not provided
Not provided
Not provided
Not provided
|
|
| One year |
| Number of patients with vascular graft disease. | One year |
| Number of patients with other bacterial or viral opportunistic infections. | One year |
| Number of patients with leukopenia secondary to prophylaxis. | One year |
| Number of patients with neutropenia secondary to prophylaxis. | One year |
| Number of leukopenia patients presenting with other bacterial infections or viral. | One year |
| Number of deceased patients during hospital admission post-heart transplant. | One year |
| Number of deceased patients, related to CMV infection, in the first year post-transplant. | One year |
| Number of deceased patients, related to CMV disease, in the first post-transplant year. | One year |
| Number of patients who died from any cause in the first year post-heart transplant. | One year |
| Title of specific Inmunoglobulin G antibodies against serum CMV. | One year |
| Title of nonspecific serum gammaglobulins. | One year |
| CMV-specific memory response B (ELISPOT B). | One year |
| Number of patients whose ELISPOT varies from low to intermediate or high risk. | One year |
| Number of patients whose ELISPOT varies from intermediate or high risk to low risk. | One year |
| Number of spots against the IE-1 antigen. | One year |
| Number of spots against the pp65 antigen. | One year |
| Number of copies of CMV DNA measured by polymerase chain reaction (PCR). | One year |
| Estimate the economic cost of both strategies studied in this clinical trial | One year |
| ID | Term |
|---|---|
| D003586 | Cytomegalovirus Infections |
| ID | Term |
|---|---|
| D006566 | Herpesviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |
Not provided
Not provided